$44M Settlement In COVID-19 Vaccine Securities Suit Gets Final Approval

Mealey's (January 23, 2023, 2:41 PM EST) -- PHILADELPHIA — A federal judge in Pennsylvania granted final approval to a settlement of more than $44 million in a securities class lawsuit against a biotechnology company and three of its senior executives who allegedly misrepresented the company’s development and manufacturing capabilities for its COVID-19 vaccine candidate, ruling that the settlement is fair, reasonable and adequate and meets all statutory requirement for approval....

Attached Documents

Related Sections